MAP2K7 and leukemia: In the primary AML cells, the KDM1A inhibitors inhibit PI3K pathway and activate the MEK pathway, further inhibition of KDM1A sequential the MEK inhibitor significantly promotes leukemia cell apoptosis especially in M5 leukemia, which was associated with protein phosphorylation and RAS mutation (169).